Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Sutherlin

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The Protein Journal|November 3, 2004
A substrate-phage approach for investigating caspase specificitySamantha Lien, Richard Pastor, Daniel Sutherlin, et al.
Journal of Pharmaceutical Sciences|May 31, 2016
Investigation of Dose-Dependent Factors Limiting Oral Bioavailability: Case Study With the PI3K-δ InhibitorPo-Chang Chiang, Daniel Sutherlin, Jodie Pang, et al.
Mini Reviews in Medicinal Chemistry|June 10, 2008
On the edge of validation--cancer protease fibroblast activation proteinBeni B Wolf, Clifford Quan, Thuy Tran, et al.
Bioorganic & Medicinal Chemistry Letters|December 31, 2005
CDK2/cyclinA inhibitors: targeting the cyclinA recruitment site with small molecules derived from peptide leadsGeorgette Castanedo, Kevin Clark, Shumei Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 10, 2018
Mechanism-specific assay design facilitates the discovery of Nav1.7-selective inhibitorsTania Chernov-Rogan, Tianbo Li, Gang Lu, et al.
Journal of Medicinal Chemistry|July 26, 2002
Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agentsNathan J P Dubree, Dean R Artis, Georgette Castanedo, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The Protein Journal|November 3, 2004
A substrate-phage approach for investigating caspase specificitySamantha Lien, Richard Pastor, Daniel Sutherlin, et al.
Journal of Pharmaceutical Sciences|May 31, 2016
Investigation of Dose-Dependent Factors Limiting Oral Bioavailability: Case Study With the PI3K-δ InhibitorPo-Chang Chiang, Daniel Sutherlin, Jodie Pang, et al.
Mini Reviews in Medicinal Chemistry|June 10, 2008
On the edge of validation--cancer protease fibroblast activation proteinBeni B Wolf, Clifford Quan, Thuy Tran, et al.
Bioorganic & Medicinal Chemistry Letters|December 31, 2005
CDK2/cyclinA inhibitors: targeting the cyclinA recruitment site with small molecules derived from peptide leadsGeorgette Castanedo, Kevin Clark, Shumei Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 10, 2018
Mechanism-specific assay design facilitates the discovery of Nav1.7-selective inhibitorsTania Chernov-Rogan, Tianbo Li, Gang Lu, et al.
Journal of Medicinal Chemistry|July 26, 2002
Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agentsNathan J P Dubree, Dean R Artis, Georgette Castanedo, et al.
Pageof 1